A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intravenous Vedolizumab Monotherapy for the Tre